ecancer
Avatar

ASCO® 2023 Insights: "Dr. Roy Herbst on ADAURA Trial OS Analysis of Adjuvant Osimertinib in Patients With Resected EGFRm Stage IB–IIIA NSCLC"

By ecancer FEATURING Roy Herbst
By ecancer FEATURING Roy Herbst
424 views
June 14, 2023
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
35:40
Balazs Halmos

Year in Review: Lung Cancer

11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
14:49
Vivek Subbiah

Year in Review: Precision Medicine

05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
54:26
Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst
06:20
Blanca Ledezma

Practical Guidance for the Management of Adverse Events in Patients …

26:42
Total Health

ADAURA & KEYNOTE-671 Trials: Early Stage NSCLC Updates - 2023 AS…

Feat. J. Bauman
17:57
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Expert Discussion on New Treatment Options…

Feat. D. Carbone, B. Stiles
21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

08:15
ecancer

ESMO 2023 Summary: "Highlights From Recent NSCLC Trials"

Feat. B. Gyawali
23:29
2023 Evolution Conference

IO and Targeted Treatment for mNSCLC

Feat. M. Mooradian